Integrated approaches to maximizing maize resistance to fall armyworm
CABI Reviews,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 20, 2025
Abstract
Fall
armyworm
(FAW)
is
a
serious
pest
of
maize
causing
major
yield
loss
throughout
the
world.
FAW
management
not
easy
primarily
due
to
its
ability
migrate
into
areas
lacking
resistant
cultivars,
lack
diapause,
and
evolving
resistance
control
measures.
Here,
we
discuss
genetics
both
deployment
genetic
including
historical
breeding
efforts,
transgenic
Bt
traits,
gene
identification
studies
promote
marker-assisted
selection,
various
recent
advancements
accelerate
improvement
such
as
genome
editing,
genomic
high
throughput
phenotyping,
RNAi.
can
also
be
achieved
using
an
integrated
approach.
Challenges
IPM
include
climate
change,
complex
cropping
systems
wide
range
hosts
for
FAW.
We
suggest
that
multinational
cooperative
public
private
research
will
needed
create
insect
(IIRM)
approach
tying
together
crop,
pest,
predators;
agronomic
monitoring
methods;
changing
environment.
This
give
breeders
time
use
advanced
plant
techniques
deploy
cultivars
with
stress
resilience,
stability
grain
quality.
Language: Английский
Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from LDHC in lung adenocarcinoma
Ruifang Zhong,
No information about this author
Xiaohong Guo,
No information about this author
Chuncai Wu
No information about this author
et al.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 9, 2025
Lactate
dehydrogenase
C
(LDHC)
is
a
kind
of
cancer-testis
antigen
(CTA)
that
has
been
reported
to
be
biomarker
for
diagnosis,
efficacy
evaluation,
and
recurrence
monitoring
lung
adenocarcinoma
(LUAD).
This
study
aims
assess
the
value
LDHC
in
peptide-based
vaccines
LUAD
immunotherapy.
The
recombinant
protein
was
purified
its
effect
on
PC9
cells
evaluated
by
wound
healing
assay,
Transwell
invasion,
migration
assay.
Ten
HLA-A2-restricted
LDHC-derived
peptides
were
predicted
synthesized,
affinity
HLA-A2
molecule
analyzed
T2
binding
assay
docking.
Enzyme-linked
immunospot
(ELISpot)
LDH
cytotoxicity
performed
determine
interferon-γ
(IFN-γ)
release
level
tumor
cell
lysis
ability
peptide-induced
specific
cytotoxic
T
lymphocytes
(CTLs).
promoted
invasion
cells.
Three
P2
(LDHC170-180,
FRYLIGEKLGV),
P5
(LDHC116-124,
IMKSIIPAI),
P6
(LDHC172-180,
YLIGEKLGV)
had
high
at
50
μg/mL.
elicited
strongest
IFN-γ-secreting
lymphocyte
(CTL)
response
exhibited
potent
against
HLA-A2-positive
with
expression.
may
serve
as
targetable
immunotherapy
LUAD.
Language: Английский
Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy
ACS Applied Bio Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 12, 2025
RNA
interference
(RNAi)
has
emerged
as
a
transformative
approach
for
cancer
therapy,
enabling
precise
gene
silencing
through
small
interfering
(siRNA).
However,
the
clinical
application
of
siRNA-based
treatments
faces
challenges
such
rapid
degradation,
inefficient
cellular
uptake,
and
immune
system
clearance.
Nanotechnology-enhanced
siRNA
delivery
revolutionized
therapy
by
addressing
these
limitations,
improving
stability,
tumor-specific
targeting,
therapeutic
efficacy.
Recent
advancements
in
nanocarrier
engineering
have
introduced
innovative
strategies
to
enhance
safety
precision
therapies,
offering
new
opportunities
personalized
medicine.
This
review
highlights
three
key
innovations
nanotechnology-enhanced
delivery:
artificial
intelligence
(AI)-driven
design,
multifunctional
nanoparticles
combined
strategies,
biomimetic
nanocarriers
enhanced
biocompatibility.
AI-driven
utilize
machine
learning
algorithms
optimize
nanoparticle
properties,
drug
release
profiles
minimizing
off-target
effects.
Multifunctional
integrate
with
chemotherapy,
immunotherapy,
or
photothermal
synergistic
treatment
approaches
that
outcomes
reduce
resistance.
Biomimetic
nanocarriers,
including
exosome-mimicking
systems
cell-membrane-coated
nanoparticles,
improve
circulation
time,
evasion,
targeted
tumor
delivery.
These
collectively
precision,
efficiency,
therapies.
The
scope
novelty
lie
their
ability
overcome
primary
barriers
while
paving
way
clinically
viable
solutions.
provides
comprehensive
analysis
latest
developments
fabrication,
preclinical
studies,
assessments.
By
integrating
multifunctionality,
biomimicry,
holds
immense
potential
future
therapy.
Language: Английский
Advances in RNA-Based Therapeutics: Challenges and Innovations in RNA Delivery Systems
Current Issues in Molecular Biology,
Journal Year:
2024,
Volume and Issue:
47(1), P. 22 - 22
Published: Dec. 31, 2024
Nucleic
acids,
as
carriers
of
genetic
information,
have
found
wide
applications
in
both
medical
and
research
fields,
including
gene
editing,
disease
diagnostics,
drug
development.
Among
various
types
nucleic
RNA
offers
greater
versatility
compared
to
DNA
due
its
single-stranded
structure,
ability
directly
encode
proteins,
high
modifiability
for
targeted
therapeutic
regulatory
applications.
Despite
promising
potential
biomedicine,
RNA-based
medicine
still
faces
several
challenges.
Notably,
one
the
most
significant
technical
hurdles
is
achieving
efficient
delivery
while
minimizing
immune
responses.
Various
strategies
been
developed
delivery,
viral
vectors,
virus-like
particles
(VLPs),
lipid
nanoparticles
(LNPs),
extracellular
vesicles
(EVs).
In
this
review,
we
explore
these
methods,
highlight
their
advantages
limitations,
discuss
recent
advancements,
providing
insights
future
therapeutics.
Language: Английский